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Abstract: Using results from our previously reported cyclic opioid
peptide series and reliable models for l-, d-, and j-opioid receptors
(MOR, DOR, and KOR, respectively) and their complexes with
peptide ligands, we have designed and synthesized a series of cyclic
pentapeptides of structure Tyr-c[D-Cys-Phe-Phe-X]-NH2, cyclized via
disulfide, methylene, or ethylene dithioethers, and where X ¼ D- or
L-Cys; or D- or L-penicillamine (Pen; b,b-dimethylcysteine).
Determination of binding affinities to MOR, DOR, and KOR
revealed that members of this series with X ¼ D- or L-Cys display
KOR affinities in the low nanomolar range, demonstrating that a
DPDPE-like tetrapeptide scaffold is suitable not only for DOR and
MOR ligands, but also for KOR ligands. The cyclic pentapeptides
reported here are not, however, selective for KOR, rather they
display significant selectivity and high affinity for MOR. Indeed,
peptide 8, Tyr-c[D-Cys-Phe-Phe-Cys]-NH2-cyclized via a methylene
dithioether, shows picomolar binding affinity for MOR (Kli ¼
16 pM) with more than 100-fold selectivity for MOR vs. DOR or KOR,
and may be of interest as a high affinity, high selectivity MOR
ligand. Nonetheless, the high affinity KOR peptides in this series
represent excellent leads for the development of structurally
related, selective KOR ligands designed to exploit structurally
specific features of KOR, MOR, and DOR.
Abbreviations: CHO, Chinese hamster ovary; C6, rat C6 glioma; EL,
extracellular loop; Pen, penicillamine; RP-HPLC, reverse phase high-
performance liquid chromatography; TM, transmembrane a-helix.
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Introduction
Understanding the differences in structure and function of
opioid receptors and of the modes of their interactions with
ligands is fundamental for rational design of safer analge-
255
sics. Small peptides and truncated endogenous ligands can
serve as tools for this task. The cloning of the human opioid
receptor types: d (DOR) (1,2), l (MOR) (3–5), and j (KOR)
(3,6–8) in the early 1990s has enabled a more thorough
study of the ligand-binding site and development of receptor
selective ligand pharmacophores. Sequence variability of
homologous MOR, DOR, and KOR in the region of ligand
binding predisposes the opioid receptor types for structur-
ally dissimilar ligands.
Because of an inherently restricted number of conforma-
tions, short cyclized peptides have been extensively used as
probes of receptor-binding sites, which has allowed more
detailed exploration of spatial requirements for ligand
binding at opioid receptors. Previously, we have success-
fully merged two approaches to examine receptor–peptide
interactions: design of small cyclic peptides and modeling
of ligand–receptor complexes. This methodology has
resulted in the development of ligand–receptor interaction
models for two closely related peptides that are selective for
DOR and MOR, JOM-13 [Tyr-c(SS)[d-Cys-Phe-d-Pen]-OH,
cyclized through the residues 2 and 4 side chain thiols to a
disulfide] and JOM-6 [Tyr-c(SEtS)[d-Cys-Phe-d-Pen]-NH
2
,
cyclized through the side chain thiols to an ethylene
dithioether], respectively (9,10; http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?cmd¼Retrieve&db¼pubmed&dopt¼
Abstract&list_uids¼12464111).
The challenge remains, however, to decipher the specific
pharmacophore of KOR. It is known that endogenous Leu-
enkephalin (YGGFL) binds and activates only MOR and
DOR, but not KOR, while the larger endogenous peptide,
dynorphin A (YGGFLRRIRPKLKWDNQ), is a potent KOR
agonist (11). Truncation and substitution studies on
dynorphin A demonstrated that Arg7, Lys11, and Lys13 are
essential for high affinity and potency of dynorphin A to
KOR (12), while the basic character of Arg6 is important for
KOR-selectivity (13). Therefore, it was assumed that the
extension of the address moiety enriched by positively
charged residues is required for KOR-activity of enkephalin-
like peptides. Consequently several dynorphin-related
undecapeptides either linear or cyclized by lactam bridge
between residues 2 and 5 were designed, which demon-
strated high j-binding affinity and moderate selectivity (14).
However, we have recently shown that KOR-active pep-
tides can be developed using a relatively rigid cyclic tetra-
peptide scaffold similar to that of JOM-13 (15). A cyclic
tetrapeptide, Tyr-c[d-Cys-Phe-d-Cys]-NH2 (MP-133)-cyc-
lized via a disulfide, exhibited high binding affinity toward
all opioid receptors, including KOR (Kji ¼ 38.7 nm). We
observed that d-Cys, rather than d-Pen, in the fourth
position was essential for high KOR-binding affinity.
Indeed, the substitution of d-Cys to a larger b-gem-dime-
thylcysteine (d-Pen) precluded binding to KOR, but did not
affect binding to MOR and DOR. Moreover, the presence of
small aromatic side chain in the third position (Phe3) of the
cyclic tetrapeptides was also required for KOR activity,
while larger aromatic and aliphatic side chains were well
tolerated only by MOR and DOR. Comparison of MOR,
DOR, and KOR homology models allowed the suggestion
that the high bias of KOR toward Phe3 and d-Cys4 is related
to the smaller size of the KOR-binding pocket in the region
that accommodates the third and fourth peptide residues.
Modeling studies demonstrated that the binding pocket for
the cyclic opioid peptides is located between transmem-
brane (TM) helices 3–7, and is partially filled by extracel-
lular loop 2 (EL-2), which in KOR is three-residues longer
than in DOR or MOR, resulting in less space available for
ligand. The requirement for an amidated vs. anionic C-ter-
minus in these tetrapeptide ligands is a consequence of




ively well to KOR, its MOR affinity is approximately 30-fold
higher, a consequence of the constrained KOR-binding
pocket which requires a binding conformation of the peptide
tripeptide cycle that is approximately 2 kcal/mole higher
than its lowest energy state. Here, we describe alternate
scaffolds designed to accommodate the requirements of the
KOR-binding site with a reduced energetic penalty. In par-






0, 1, 2), where X represents d- or l-Cys or d- or l-Pen, which
display significantly improved KOR affinity.
Experimental Procedures
Materials
All Fmoc-protected amino acid were obtained from
Advanced ChemTech (Louisville, KY, USA) or Chem-Im-
pex International (Wood Dale, IL, USA). All other reagents
were from Sigma-Aldrich (Milwaukee, WI, USA) unless
otherwise indicated.
Solid phase peptide synthesis
All peptides were synthesized by solid phase methods on an
ABI Model 431A solid phase peptide synthesizer (Applied
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Biosystems, Foster City, CA, USA). Rink resin (Advanced
ChemTech) was used as the solid support for C-terminal
carboxamide peptides. Peptide elongation on the peptide-
resin involved treating resin with piperidine (Aldrich) to
cleave the Fmoc-protecting group, followed by coupling of
the next amino acid with o-benzotriazol-1-yl-N,N,N¢,N¢-
tetramethyl uronium hexafluorophosphate (HBTU) and
1-hydroxybenzotriazole (HOBt; Applied Biosystems). A
solution of trifluoroacetic acid/H2O/thioanisole/ethylene-
dithiol (9 : 0.5 : 0.25 : 0.25, v/v/v/v) was used to cleave the
linear peptide from the resin and simultaneously remove
the side chain-protecting groups. The peptide solution was
filtered from the resin and then subjected to preparative
reverse phase high-performance liquid chromatography
(RP-HPLC) to afford the linear disulfhydryl-containing
peptide. Final product confirmation was obtained by ESI-
LC-MS (ThermoFinnigan, San Jose, CA, USA).
General method for disulfide cyclization of peptides
To obtain disulfide-cyclized peptide, linear disulfhydryl-
containing peptide was dissolved in a 1% (v/v) acetic acid
(HOAc) in H
2
O solution (saturated with N
2
) at 5 C (1 mg
linear peptide/mL of aqueous HOAc solution). The pH of the
peptide solution was raised to 8.5 using NH
4
OH, followed





was stirred for 1 min then quenched by adjusting the pH to
3.5 with HOAc. The mixture was then subjected to prepar-
ative RP-HPLC to afford the disulfide-cyclized peptide.
General method for dithioether cyclization of peptides
To form dithioether-containing cyclic peptides, linear di-
sulfhydryl peptide was added to dimethylformamide and
maintained at 5 C under a N2 atmosphere (0.1 mg linear
peptide/mL dimethylformamide). About 10 mEq of potas-
sium t-butoxide were added to the peptide solution, fol-
lowed by the addition of 10 mEq of Br-(CH2)n-Br (n ¼ 1 or
2). The reaction was quenched with 5 mL HOAc after 2 h
and the solvent was removed in vacuo. The residue was
dissolved in water, filtered, and then subjected to prepara-
tive RP-HPLC to afford the alkyl dithioether-cyclized pep-
tide.
All final product peptides were >95% pure as assessed by
RP-HPLC on a Vydac 218TP C-18 column (The Nest Group,
Southboro, MA, USA) using the solvent system 0.1% tri-
fluoroacetic acid (TFA) in water/0.1% TFA in acetonitrile
by a gradient of 0–70% organic component in 70 min,
monitored at 230 nm, and all peptides displayed the
appropriate molecular weights as determined by mass
spectrometry (Table 1).
Radioligand-binding assays
Opioid ligand-binding assays were based on the displace-
ment by the test compounds of radiolabeled 3H-diprenor-
phine from membrane preparations containing opioid
receptors [human KOR stably expressed in Chinese hamster
ovary (CHO) cells (16) or rat MOR and DOR receptors stably
expressed in C6 cells (17)]. The assay mixture, containing
membrane suspension in 50 mm Tris buffer (pH 7.4), radi-
olabeled ligand (0.2 nm), and test compound, was incubated
at 25 C for 1 h to allow binding to reach equilibrium.
Subsequently, the samples were filtered rapidly, and the
radioactivity retained was determined by liquid scintilla-
tion counting. Inhibition of radiolabeled ligand binding by
the test compounds was determined from maximal specific
binding, measured with an appropriate excess of unlabeled
naloxone (10 lm). IC50-values were determined by nonlin-
ear regression analysis to fit a logistic equation to the
competition data using graphpad prism Software. The
results presented are the mean ± SEM from at least three
separate assays, each performed in duplicate.











1 706.3 707.2 30.1
2 720.3 721.1 35.0
3 734.3 735.2 30.2
4 706.3 707.2 30.4
5 720.3 721.2 32.2
6 734.3 735.3 32.6
7 678.2 679.1 30.2
8 692.3 693.1 30.6
9 706.3 707.1 31.1
10 678.2 679.1 28.9
11 692.3 693.2 31.4
12 706.3 707.1 32.2
a. Molecular weight was determined by ESI-LCMS, positive
mode.
b. Retention time assessed by analytical RP-HPLC: 0–70% ACN
w/0.1% TFA in 70 min, 230 nm, samples in H2O w/0.1% TFA
(elution column heated at 35 C).
RP-HPLC, reverse phase high-performance liquid chromatogra-
phy; TFA, trifluoroacetic acid.
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Modeling of complex of KOR with cyclic pentapeptide
The comparative modeling of the active conformation of
human KOR (residues 55–348, accession code P41145) in
complex with cyclic pentapeptide 10, Tyr-c[d-Cys-Phe-
Phe-d-Cys]-NH2(SS), was done using the distance geom-
etry program diana (18) and the structural template of the
active conformation of MOR, as described previously (15).
The active conformation of MOR was calculated from the
rhodopsin crystal structure (1gzm) (19) and structural
constraints corresponding to the active states of different
G protein-coupled receptors (GPCRs) (10). The position of
the pentapeptide ligand inside KOR was restricted by
H-bond distance constraints (O…N and O…O distances of
3.5 Å) between Tyr1 (N+) of the peptide and Asp138 (COO-)
and Glu209 (COO-) of KOR, and between Tyr1 Og of pep-
tide and Ala234 (C¼O) and His291 (Ne2) of KOR. Moreover,
the arrangement of the pentapeptide depends on the ori-
entations of several residues in the binding pocket of
KOR, such as Phe212, Lys227, Glu297, and Tyr312. The
rotamers of these side chains that provided favorable
interactions with ligand, devoid of hindrances, were
defined during calculations.
The backbone dihedral angles for residues 2–5 of penta-
peptide 10 were restricted to the L-, R-, R-, and P-domains
of the Ramachandran plot, respectively, consistent with
the crystal structure of tetrapeptide cycle of the DPDPE
analog, Tyr-c[d-Pen-Ala-Phe-d-Pen]OH(SS) (20), because
we assumed that these analogous pentapeptides, which
possess high binding affinity to DOR, are likely to adopt
similar conformations in the DOR-binding pocket. The
pentapeptide 10, which binds with high affinity to all
opioid receptors (Table 2), presumably adopts comparable
conformations (at least for the 14-membered ring) in
complexes with all opioid receptors. Indeed, the compar-
ison of complexes of opioid receptors with selective cyclic
tetrapeptides demonstrated good superposition of their
cycles and of their major exocyclic pharmacophore
elements, the Tyr1 amine and side chain (9,15,21), as well
as the Phe3 side chain in MOR and KOR tetrapeptide lig-
ands (15). Moreover, we concluded that aromatic side
chains of Tyr1 and Phe3 in 10 would occupy trans-rotam-




with KOR (15), while the Phe4 side chain would favor the
gauche-rotamer, to provide favorable interactions with
Phe3 side chain of the pentapeptide. These assumptions
were supported by subsequent distance geometry calcula-
tions, which resulted in well-defined structures (r.m.s.d.
between all Ca-atoms of 10 best calculated models of lig-
and–receptor complexes was <0.7 Å) that satisfied the
spatial constraints (target function <30), imposed on the
active conformations of KOR and on the receptor-bound
conformation of pentapeptide 10.
Table 2. Opioid receptor-binding affinity of cyclic pentapeptide analogs
Peptide sequence Bridgea Analog
Ki (nM; ±SEM)
l d j
[N-Met-Tyr1, N-Met-Arg7-D-Leu8]-DynA(1–8)-EtNH2 – E2078 0.1 ± 0.01 1.5 ± 0.06 0.67 ± 0.08
Tyr-c[D-Cys-Phe-D-Cys]-NH2 SS MP-133 1.26 ± 0.25 16.1 ± 3.8 38.7 ± 1.84
Tyr-c[D-Cys-Phe-Phe-D-Pen]-NH2 SS 1 0.11 ± 0.02 2.0 ± 1.0 151 ± 54.4
Tyr-c[D-Cys-Phe-Phe-D-Pen]-NH2 SMeS 2 0.4 ± 0.07 26 ± 7 31 ± 9
Tyr-c[D-Cys-Phe-Phe-D-Pen]-NH2 SEtS 3 0.14 ± 0.06 40 ± 6.0 42.0 ± 18.0
Tyr-c[D-Cys-Phe-Phe-L-Pen]-NH2 SS 4 0.40 ± 0.22 2.6 ± 1.0 66.3 ± 18.1
Tyr-c[D-Cys-Phe-Phe-L-Pen]-NH2 SMeS 5 0.11 ± 0.02 3.5 ± 1.0 21.7 ± 9.39
Tyr-c[D-Cys-Phe-Phe-L-Pen]-NH2 SEtS 6 0.41 ± 0.02 34 ± 6.7 42.0 ± 20.0
Tyr-c[D-Cys-Phe-Phe-L-Cys]-NH2 SS 7 0.27 ± 0.20 0.8 ± 0.3 8.63 ± 5.0
Tyr-c[D-Cys-Phe-Phe-L-Cys]-NH2 SMeS 8 0.016 ± 0.01 1.8 ± 0.8 2.5 ± 1.5
Tyr-c[D-Cys-Phe-Phe-L-Cys]-NH2 SEtS 9 0.19 ± 0.01 5.4 ± 0.7 4.59 ± 1.8
Tyr-c[D-Cys-Phe-Phe-D-Cys]-NH2 SS 10 0.05 ± 0.01 0.4 ± 0.09 1.6 ± 0.5
Tyr-c[D-Cys-Phe-Phe-D-Cys]-NH2 SMeS 11 0.03 ± 0.01 2.5 ± 0.7 2.7 ± 0.7
Tyr-c[D-Cys-Phe-Phe-D-Cys]-NH2 SEtS 12 0.12 ± 0.06 5.9 ± 2 14 ± 3
a. Bridge between the second and the last amino acids: SS, disulfide bridge; SMeS, S-CH2-S; SEtS, S-CH2-CH2-S.
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Results and Discussion
In order to improve the KOR affinity displayed by the cyclic
tetrapeptide Tyr-c[d-Cys-Phe-d-Cys]-NH2(SS) (MP-133), at
firstwe chose to examine cyclic pentapeptides patterned on a
DPDPE-like scaffold. Lead compound 1, Tyr-c[d-Cys-Phe-
Phe-d-Pen]-NH2(SS), can be viewed as a DPDPE analog with
expected low-energy conformations of its tetrapeptide cycle
that are similar to [Ala3]DPDPE (see Experimental Proce-
dures). Such cycle conformations allow approximate fit to
the binding pockets of DOR, MOR, and KOR and thus could
avoid the conformational energy penalty imposed on
MP-133. Moreover, 1 can be viewed as analogous to the
MP-133 (and JOM-13, JOM-6) tetrapeptide series with an
extra Phe residue inserted as residue 4. Indeed, previous
studies have shown that cyclic pentapeptides of structure
Tyr-c[d-Cys-Phe-X-d-Pen]-NH2(SS) display high opioid
receptor affinity and behave as though JOM-13/JOM-6 ana-
logs, i.e. their critical pharmacophore elements are the Tyr1
and Phe3 residues (22). Of the pentapeptides in this series,
analogs with X ¼ Phe displayed the most promising KOR
affinity (unpublished observations) and hence served as the
starting point for the present study. Pentapeptides-like 1 can
be viewed as retaining the essential features that allow good
KOR affinity of MP-133, while relaxing the ring conforma-
tional constraints to allow binding of a low-energy peptide
conformer. In order to further probe the optimal features for
KOR binding in this series, we examined a series of cyclic
pentapeptides of structure Tyr-c[d-Cys-Phe-Phe-X]-NH
2
,
where X ¼ d- or l-Pen, or d- or l-Cys, and where cyclization
is effected via disulfide, methylene dithioether, or ethylene
dithioether. Results are summarized in Table 2 which also
contains reference data for MP-133 and the dynorphin ana-
log, E2078, a KOR reference ligand.
Several straightforward conclusions regarding the KOR
affinity of the cyclic pentapeptides are evident from
Table 2. First and most significantly, the results indicate
that the goal of enhancing KOR affinity by enlarging the
ring cycle has been realized; analogs 8–11 all display KOR
affinities <5 nm. As in the tetrapeptide series, a C-terminal
Cys residue provides considerable improvement in KOR
affinity relative to a C-terminal Pen residue. This
improvement is especially profound in the case of analogs 1
vs. 10, where replacement of d-Pen by d-Cys results in
approximately 100 improvement in KOR affinity. By con-
trast, stereochemistry of the C-terminal residue has only a
minor effect: KOR affinities are fairly similar for the cor-
responding diastereomers 1 and 4; 2 and 5; 3 and 6, etc.
Likewise, mode of cyclization has a relatively minor effect,
with a slight preference for the smaller disulfide or
methylene dithioether analogs.
In order to understand the mode of interaction of the
cyclic pentapeptides with the KOR-binding site, the com-
plex of the active conformation of KORwith pentapeptide 10
was calculated using distance geometry, as described in
Experimental Procedures. The calculated model of KOR is
close to the crystal structure of rhodopsin (19) with r.m.s.d.
of 2.2 Å for 212 common Ca-atoms in the seven TM bundle.
The difference is mostly attributed to the largemovement of
TM6, shift of EL-2 and smaller adjustments in the positions
Table 3. Torsion angles () for the calculated receptor-
bound conformation of pentapeptide 10, Tyr-c[D-Cys-
Phe-Phe-D-Cys]-NH2(SS) in comparison with X-ray
































Przydzial et al. High affinity cyclic pentapeptide ligands
J. Peptide Res. 66, 2005 / 255–262 259
Figure 1. The superposition of pentapeptide 10, Tyr-c[d-Cys-Phe-Phe-d-Cys]-NH2 (SS bridge), and tetrapeptide MP-133, Tyr-c[d-Cys-Phe-d-Cys]-NH2
(SS bridge), in the binding pocket of human j-opioid receptor (KOR). Pentapeptide 10 is shown by thick lines and MP-133 by thin lines in (A) and
vice versa in (B). Ligand and receptor residues are colored by atom type: oxygen is denoted by red, nitrogen by blue, sulfur by yellow, carbon by
purple (ligand) or green (receptor residues). Both pentapeptide and tetrapeptide are positioned in the KOR-binding pocket similarly, except for the
orientation of the C-terminal amide and the presence of Phe4 in the pentapeptide, which requires the rotation of Phe214 from extracellular loop (EL)-2
of KOR.
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of other TM helices, which are the characteristic features of
the activated MOR template (10).
The calculated model of KOR with pentapeptide 10 is
nearly identical to the model of KOR with the tetrapeptide
MP-133 (15), except for different orientations of several side
chains in the binding pocket (Phe212, Lys227, and Glu297).
The dihedral angles of the calculated receptor-bound con-
formation of peptide 10 are close to those in the X-ray
structure of [l-Ala3]DPDPE (Table 3). Tyr1 and Phe3 of
peptide 10 and MP-133 are similarly positioned in the
binding pocket (Fig. 1). Specifically, the N-terminal nitro-
gen and the phenolic oxygen of Tyr1 in both peptides form
multiple H-bonds with Asp138 (COO-), Glu209 (COO-),
His297 (Ne2), and Ala234 (backbone carbonyl) of KOR, and
the Tyr1 phenolic ring is surrounded by aromatic and sulfur-
containing sides chains from TM3 (Tyr139, Met142, Phe143),
TM5 (Phe231), and TM6 (Trp287). Phe3 of both peptides
interacts with the aromatic side chain of Tyr312 and with
Ile316 from TM7 and is enclosed by side chains of mainly
acidic residues from EL-2 (Asp204, Asp206, Val207, Glu209).
The peptide disulfide bridge is located in a tight pocket
between EL-2 (Leu212) and the extracellular ends of TM5
(Lys227) and TM6 (Glu297). The size of this area is much
smaller in KOR than in MOR and DOR, due to the presence
of an extra-residue in EL-2 near TM5. The small size of the
binding pocket in this area cannot accommodate the bulky
b,b-dimethyl groups of d-Pen5 (or d-Pen4)-containing
enkephalin analogs without substantial hindrances with
receptor residues, particularly with Pro215, Lys227, and
Glu297. This is consistent with the strong preference of
C-terminal d-Cys over d-Pen for KOR recognition. Minor
differences in the position of pentapeptides vs. tetrapeptides
within the KOR-binding site results from the presence of
Phe4 in pentapeptide 10, which interacts with backbone and
side chains of EL-2 (Arg202, Asp204, Ser211, and Phe214), and
from the relocation of the C-terminal amide group of the
peptide ligand: -CONH2 of MP-133 is located in the open
space between EL-2 (Phe214) and TM6 (Glu297), while -
CONH2 of peptide 10 is more buried between EL-2 (Gln
213,
Pro215) and the end of TM5 (Asp223, Met226).
Our results demonstrate that very similar cyclic scaffolds
can be utilized for high affinity peptide ligands for all three
opioid receptors, a result that diverges from existing SAR
that suggests only longer dynorphin-like peptides are suit-
able for KOR binding. In particular, analogs 8–11 exhibit
low nanomolar KOR affinity, comparable with standard,
dynorphin-based ligands. However, although high KOR
affinity is exhibited within this series, none of the analogs
is selective for KOR. Indeed, peptides 8, 10, and 11, display
extremely high MOR affinity (Kli ¼ 16 pm, K
l
i ¼ 50 pm, and
Kli ¼ 30 pm, respectively), higher even than Schiller and
co-workers [Dmt]DALDA [Ki  150 pm (23)], and may be
of future interest as MOR ligands. Further modifications of
these pentapeptides are required to obtain KOR selectivity.
Modeling of KOR in complex with the highest affinity KOR
pentapeptide 10 suggests j-specific interactions between
receptor residues and pentapeptide that can be targeted to
enhance selectivity. For example, Phe3 of the peptide ligand
is surrounded by several acidic residues from EL-2. There-
fore, Phe3 could be modified to a side chain with more basic
properties to enhance KOR-specific ionic interactions with
acidic residues from EL-2 (Asp204, Asp206). These and other
modification aimed at improving KOR selectivity by
increasing KOR affinity, while reducing MOR and DOR
affinity are in progress.
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